yongkc personal page - To The Moon

yongkc

yongkc

No personal profile

10Follow

0Followers

0Topic

0Badge

2021-07-07

Like

Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%

2021-07-07

Later

U.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4088206167013860,"uuid":"4088206167013860","gmtCreate":1625388194058,"gmtModify":1625394486873,"name":"yongkc","pinyin":"yongkc","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9fe7f2f331c630266276073a95e82535","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":10,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":140003122,"gmtCreate":1625617929766,"gmtModify":1703744926566,"author":{"id":"4088206167013860","authorId":"4088206167013860","authorIdStr":"4088206167013860","name":"yongkc","avatar":"https://static.tigerbbs.com/9fe7f2f331c630266276073a95e82535","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088206167013860"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140003122","repostId":"2149936563","repostType":4,"repost":{"id":"2149936563","pubTimestamp":1625583201,"share":"https://ttm.financial/m/news/2149936563?lang=&edition=fundamental","pubTime":"2021-07-06 22:53","market":"us","language":"en","title":"Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2149936563","media":"Benzinga","summary":"Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to ","content":"<ul>\n <li>Armed with new data from its development partner&nbsp;<b>Bharat Biotech</b>,&nbsp;<b>Ocugen Inc</b>&nbsp;(NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada.</li>\n <li>Covaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.</li>\n <li>New data from the 25,800-patient Phase 3 trial show that the shot has an&nbsp;overall protective efficacy of 77.8%&nbsp;and 65.2% against the highly transmissible delta (B.1.617.2) variant.</li>\n <li>The two-dose vaccine based on an inactivated form of the virus formulated with an immune-boosting adjuvant showed to be 93.4% protective against severe symptomatic COVID-19.</li>\n <li>Adverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.</li>\n <li>Ocugen recently announced that it will pursue submission of a Biologics License Application (BLA) for its COVID-19 vaccine candidate in the U.S. and has initiated discussions with Health Canada for regulatory approval.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are up 14.3% at $8.33 during the premarket session on the last check Tuesday.</li>\n</ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NGD":"New Gold"},"source_url":"https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149936563","content_text":"Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada.\nCovaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.\nNew data from the 25,800-patient Phase 3 trial show that the shot has an overall protective efficacy of 77.8% and 65.2% against the highly transmissible delta (B.1.617.2) variant.\nThe two-dose vaccine based on an inactivated form of the virus formulated with an immune-boosting adjuvant showed to be 93.4% protective against severe symptomatic COVID-19.\nAdverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.\nOcugen recently announced that it will pursue submission of a Biologics License Application (BLA) for its COVID-19 vaccine candidate in the U.S. and has initiated discussions with Health Canada for regulatory approval.\nPrice Action: OCGN shares are up 14.3% at $8.33 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140000377,"gmtCreate":1625617829999,"gmtModify":1703744923955,"author":{"id":"4088206167013860","authorId":"4088206167013860","authorIdStr":"4088206167013860","name":"yongkc","avatar":"https://static.tigerbbs.com/9fe7f2f331c630266276073a95e82535","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088206167013860"},"themes":[],"htmlText":"Later","listText":"Later","text":"Later","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140000377","repostId":"1122166072","repostType":4,"repost":{"id":"1122166072","pubTimestamp":1625613844,"share":"https://ttm.financial/m/news/1122166072?lang=&edition=fundamental","pubTime":"2021-07-07 07:24","market":"fut","language":"en","title":"U.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1122166072","media":"CNBC","summary":"U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.Dow Jones Industrial Average futures fell by 54 points, or 0.16%. S&P 500 and $Nasdaq$ 100 futures dipped 0.10% and 0.06%, respectively.During the regular session, the 30-stock Dow fell 208.98 points, or 0.6%. The S&P 500 ended the day down by 0.2%. The Nasdaq Composite rose nearly 0.2%. The tech-heavy index rose to a fresh all-time high on Tuesday.$Investors$ may b","content":"<div>\n<p>U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.\nDow Jones Industrial Average futures fell by 54 points, or 0.16%. S...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 07:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.\nDow Jones Industrial Average futures fell by 54 points, or 0.16%. S...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF",".SPX":"S&P 500 Index","OEX":"标普100","SDS":"两倍做空标普500ETF","SPXU":"三倍做空标普500ETF","SSO":"两倍做多标普500ETF","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","IVV":"标普500指数ETF"},"source_url":"https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1122166072","content_text":"U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.\nDow Jones Industrial Average futures fell by 54 points, or 0.16%. S&P 500 and Nasdaq 100 futures dipped 0.10% and 0.06%, respectively.\nDuring the regular session, the 30-stock Dow fell 208.98 points, or 0.6%. The S&P 500 ended the day down by 0.2%. The Nasdaq Composite rose nearly 0.2%. The tech-heavy index rose to a fresh all-time high on Tuesday.\nInvestors may be worried the economy might be approaching its peak and that a correction could be on the way. In addition to complacency in the market, the combination of profit-margin pressures, inflation fears, Fed tapering and possible higher taxes could contribute to an eventual drawdown, market strategists say.\nRecovery-centered stocks likeCaterpillar,ChevronandJPMorgan Chasepulled back Tuesday while Big Tech stocks likeAmazon,AppleandAlphabetgained. Energy stocks took a hit after West Texas Intermediate crude futures hit their highest level in more than six years before turning negative.\nThe 10-year Treasury yield fell 7.2 basis points to 1.36% as investors react to the potential of slower economic growth. That was its lowest level since February. The yield on the 30-year Treasury bond was 6.4 basis points lower at 1.98%.\nInvestors will be listening more clues on the direction of the Federal Reserve’s monetary policy when it releases its latest meeting minutes Wednesday afternoon, which could be a catalyst for a move in both bonds and stocks.\nThe Fed’s minutes are expected to be dovish with the central bank looking for progress in the labor market and not worried that recent inflation will become a persistent trend. Slowing down the bond buying would be the Fed’s first major retreat from the easy policies it put in place when the economy shut down last year.\nThe end of the Fed’s $120 billion a month in Treasury and mortgage purchases would also signal that the central bank’s next move could be to raise interest rates.\nWeekly mortgage applications and the Job Openings and Labor Turnover Survey are also scheduled to be released Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":140000377,"gmtCreate":1625617829999,"gmtModify":1703744923955,"author":{"id":"4088206167013860","authorId":"4088206167013860","authorIdStr":"4088206167013860","name":"yongkc","avatar":"https://static.tigerbbs.com/9fe7f2f331c630266276073a95e82535","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088206167013860"},"themes":[],"htmlText":"Later","listText":"Later","text":"Later","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140000377","repostId":"1122166072","repostType":4,"repost":{"id":"1122166072","pubTimestamp":1625613844,"share":"https://ttm.financial/m/news/1122166072?lang=&edition=fundamental","pubTime":"2021-07-07 07:24","market":"fut","language":"en","title":"U.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1122166072","media":"CNBC","summary":"U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.Dow Jones Industrial Average futures fell by 54 points, or 0.16%. S&P 500 and $Nasdaq$ 100 futures dipped 0.10% and 0.06%, respectively.During the regular session, the 30-stock Dow fell 208.98 points, or 0.6%. The S&P 500 ended the day down by 0.2%. The Nasdaq Composite rose nearly 0.2%. The tech-heavy index rose to a fresh all-time high on Tuesday.$Investors$ may b","content":"<div>\n<p>U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.\nDow Jones Industrial Average futures fell by 54 points, or 0.16%. S...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock futures are slightly lower after S&P 500 snaps 7-day winning streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 07:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.\nDow Jones Industrial Average futures fell by 54 points, or 0.16%. S...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF",".SPX":"S&P 500 Index","OEX":"标普100","SDS":"两倍做空标普500ETF","SPXU":"三倍做空标普500ETF","SSO":"两倍做多标普500ETF","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","IVV":"标普500指数ETF"},"source_url":"https://www.cnbc.com/2021/07/06/stock-market-futures-open-to-close-news.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1122166072","content_text":"U.S. stock futures opened slightly lower Tuesday night after the S&P 500 ended a seven-day winning streak, its longest since August.\nDow Jones Industrial Average futures fell by 54 points, or 0.16%. S&P 500 and Nasdaq 100 futures dipped 0.10% and 0.06%, respectively.\nDuring the regular session, the 30-stock Dow fell 208.98 points, or 0.6%. The S&P 500 ended the day down by 0.2%. The Nasdaq Composite rose nearly 0.2%. The tech-heavy index rose to a fresh all-time high on Tuesday.\nInvestors may be worried the economy might be approaching its peak and that a correction could be on the way. In addition to complacency in the market, the combination of profit-margin pressures, inflation fears, Fed tapering and possible higher taxes could contribute to an eventual drawdown, market strategists say.\nRecovery-centered stocks likeCaterpillar,ChevronandJPMorgan Chasepulled back Tuesday while Big Tech stocks likeAmazon,AppleandAlphabetgained. Energy stocks took a hit after West Texas Intermediate crude futures hit their highest level in more than six years before turning negative.\nThe 10-year Treasury yield fell 7.2 basis points to 1.36% as investors react to the potential of slower economic growth. That was its lowest level since February. The yield on the 30-year Treasury bond was 6.4 basis points lower at 1.98%.\nInvestors will be listening more clues on the direction of the Federal Reserve’s monetary policy when it releases its latest meeting minutes Wednesday afternoon, which could be a catalyst for a move in both bonds and stocks.\nThe Fed’s minutes are expected to be dovish with the central bank looking for progress in the labor market and not worried that recent inflation will become a persistent trend. Slowing down the bond buying would be the Fed’s first major retreat from the easy policies it put in place when the economy shut down last year.\nThe end of the Fed’s $120 billion a month in Treasury and mortgage purchases would also signal that the central bank’s next move could be to raise interest rates.\nWeekly mortgage applications and the Job Openings and Labor Turnover Survey are also scheduled to be released Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140003122,"gmtCreate":1625617929766,"gmtModify":1703744926566,"author":{"id":"4088206167013860","authorId":"4088206167013860","authorIdStr":"4088206167013860","name":"yongkc","avatar":"https://static.tigerbbs.com/9fe7f2f331c630266276073a95e82535","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088206167013860"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140003122","repostId":"2149936563","repostType":4,"repost":{"id":"2149936563","pubTimestamp":1625583201,"share":"https://ttm.financial/m/news/2149936563?lang=&edition=fundamental","pubTime":"2021-07-06 22:53","market":"us","language":"en","title":"Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2149936563","media":"Benzinga","summary":"Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to ","content":"<ul>\n <li>Armed with new data from its development partner&nbsp;<b>Bharat Biotech</b>,&nbsp;<b>Ocugen Inc</b>&nbsp;(NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada.</li>\n <li>Covaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.</li>\n <li>New data from the 25,800-patient Phase 3 trial show that the shot has an&nbsp;overall protective efficacy of 77.8%&nbsp;and 65.2% against the highly transmissible delta (B.1.617.2) variant.</li>\n <li>The two-dose vaccine based on an inactivated form of the virus formulated with an immune-boosting adjuvant showed to be 93.4% protective against severe symptomatic COVID-19.</li>\n <li>Adverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.</li>\n <li>Ocugen recently announced that it will pursue submission of a Biologics License Application (BLA) for its COVID-19 vaccine candidate in the U.S. and has initiated discussions with Health Canada for regulatory approval.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are up 14.3% at $8.33 during the premarket session on the last check Tuesday.</li>\n</ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NGD":"New Gold"},"source_url":"https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149936563","content_text":"Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada.\nCovaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.\nNew data from the 25,800-patient Phase 3 trial show that the shot has an overall protective efficacy of 77.8% and 65.2% against the highly transmissible delta (B.1.617.2) variant.\nThe two-dose vaccine based on an inactivated form of the virus formulated with an immune-boosting adjuvant showed to be 93.4% protective against severe symptomatic COVID-19.\nAdverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.\nOcugen recently announced that it will pursue submission of a Biologics License Application (BLA) for its COVID-19 vaccine candidate in the U.S. and has initiated discussions with Health Canada for regulatory approval.\nPrice Action: OCGN shares are up 14.3% at $8.33 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}